mProX™ Human VTCN1 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HNE2

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Cancer Research

Related Diseases

Pancreatic Cancer; Ovarian Cancer

Gene ID

Human:79679

UniProt ID

Human:Q7Z7D3

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

VTCN1, also known as B7-H4, is an immune checkpoint molecule that has been studied in various cancer types. In endometrial carcinoma, high levels of VTCN1 expression were associated with an aggressive phenotype and immunoexclusion microenvironments, indicating poor response to immune checkpoint inhibitor-based immunotherapy. In breast and ovarian cancers, an antibody-drug conjugate targeting VTCN1 showed promising results in preclinical studies, inducing complete tumor regressions. In a model of human trophoblast, VTCN1 was found to guide differentiation and suppress proinflammatory responses. In oral carcinomas, the disruption of B7/CD28 immune regulators, including VTCN1, was associated with prognosis. In malignant mesothelioma, the expression of VTCN1 was correlated with an immunosuppressive tumor microenvironment and poor survival. These studies highlight the potential of VTCN1 as a therapeutic target and prognostic marker in different cancer types.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human VTCN1 Stable Cell Line (S01YF-1023-PY171). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Skyler Smith (Verified Customer)

What is the role of VTCN1 in autoimmune diseases like vitiligo? Jun 23 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

VTCN1, a negative costimulatory molecule, shows altered expression in the blood and skin of vitiligo patients, suggesting its potential role in the development and progression of this autoimmune disease. Jun 23 2021

chat Taylor Davis (Verified Customer)

How does VTCN1 relate to type 1 diabetes (T1D)? Apr 16 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

The loss of membrane-tethered VTCN1, linked to proteolytic cleavage by nardilysin, marks T1D development, indicating the potential use of soluble VTCN1 as a T1D biomarker. Apr 16 2020

Published Data

Fig.1 Effect of VTCN1 on NPC cell proliferation.

Proliferation of HNE2 cells was assessed using the CCK-8 assay, with analysis conducted 48 hours post-infection. The results from the CCK-8 assay demonstrated a notable time-dependent reduction in cell proliferation due to VTCN1 shRNA, with decreases of 22.6%, 35.8%, and 36.8% observed at 24, 48, and 72 hours, respectively, compared to the NC group.

Ref: Song, Peng, et al. "Roles of VTCN1 in apoptosis and invasion in nasopharyngeal carcinoma." INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 9.10 (2016): 10282-10289.

Pubmed: NA

DOI: NA

Research Highlights

Hao, Jing. et al. "High DNA methylation age deceleration defines an aggressive phenotype with immunoexclusion environments in endometrial carcinoma." Frontiers in immunology, 2023.
Telomere shortening and global DNA hypomethylation have both been linked to cellular division. The latter, in particular, is known to progressively occur with each division. This phenomenon has been observed in various tissues and has been linked to aging and cancer development. Global DNA hypomethylation is characterized by a decrease in the overall methylation levels of DNA in a cell, and it is important to further understand its mechanism and potential impacts on cellular function.
Hao, Jing. et al. "High DNA methylation age deceleration defines an aggressive phenotype with immunoexclusion environments in endometrial carcinoma." Frontiers in immunology, 2023.
Pubmed: 37388735 DOI: 10.3389/fimmu.2023.1208223

Toader, Dorin. et al. "Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer." Molecular cancer therapeutics, 2023.
In the study, an investigational drug platform called Dolasynthen (DS) was developed to optimize antibody-drug conjugates (ADCs) for targeted drug delivery to tumors. This DS platform utilized a novel payload called auristatin hydroxypropylamide to achieve precise control of the drug-to-antibody ratio (DAR) and site-specific conjugation. Using this platform, a specific ADC, XMT-1660, was designed to target B7-H4 (VTCN1), a protein overexpressed in breast, ovarian, and endometrial cancers. In preclinical trials, XMT-1660 showed promising results, inducing complete tumor regression in various cancer models and demonstrating activity that correlated with B7-H4 expression.
Toader, Dorin. et al. "Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer." Molecular cancer therapeutics, 2023.
Pubmed: 37294948 DOI: 10.1158/1535-7163.MCT-22-0786